Appendiceal Cancer Treatment Market Research Report – Forecast to 2027

Appendiceal Cancer Treatment Market Research Report: By Type (Neuroendocrine Tumors, Carcinomas (Mucinous Adenocarcinoma, Goblet Cell Carcinoids, Paraganglioma), and Others, by Treatment (Surgery, Chemotherapy, and Others), by End-User– Forecast Till 2027

ID: MRFR/Pharma/5042-HCR | February 2021 | Region: Global | 100 pages

Appendiceal Cancer Treatment Market Scenario


The appendix is a tube-like structure, which is three to six inches long and is attached to the colon. It is situated in the lower right part of the abdomen. Appendiceal cancer or the cancer of the appendix is mostly found after the patients have surgery for acute appendicitis or when an abdominal mass is seen on a computerized tomography scan. The appendiceal cancer treatment market is expected to grow significantly over the forecast period.


Several factors such as a rise in targeted and innovative therapies confined to appendiceal cancer and increased awareness about the severity of the disease are anticipated to drive the growth of the market. According to the American Society of Clinical Oncology (ASCO), acute appendicitis is the most common cause in the US for an attack of severe, acute abdominal pain that requires an abdominal operation.


Additionally, in January 2018, GE Healthcare announced that it has entered into a long-term, strategic partnership with Roche Diagnostics to co-develop and market digital clinical decision support solutions. With this, the companies will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.


Appendix cancer usually does not cause symptoms until it is in an advanced stage and has spread to other parts of the body. Therefore, it becomes difficult to diagnose it in the right stage where corrective action can be taken. However, stringent government regulations about product approvals may hamper the market growth during the assessment period.


Segmentation


The appendiceal cancer treatment market has been segmented into type, treatment, and end-user.


The market, on the basis of type, has been segmented into neuroendocrine tumors and carcinomas.


The market, based on carcinomas, has been sub-segmented into mucinous adenocarcinoma, goblet cell carcinoids, intestinal-type adenocarcinoma, signet-ring cell adenocarcinoma, and paraganglioma.


The market, by treatment, has been segmented into surgery, chemotherapy, and radiation therapy.


The market, based on surgery, has been further segmented into appendectomy, hemicolectomy, and cytoreduction.


The market, based on chemotherapy, has been sub-segmented into hyperthermic intraperitoneal chemotherapy and systemic chemotherapy. The hyperthermic intraperitoneal chemotherapy segment is expected to be the largest segment due to its specificity to treat appendiceal cancer and also the high efficacy of drugs, whereas systemic chemotherapy is expected to be the fastest growing segment. This rapid growth is due to increasing awareness about the chemotherapeutic treatment and its increasing adoption rate by patients.


The market, by end-user, has been segmented into hospitals and clinics, cancer diagnostics and research institutes, and others.


Key players


AbbVie, Inc., Pfizer Inc., Eli Lilly & Company, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Becton, Dickinson & Company, Novartis AG, General Electric Company, AstraZeneca, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Sanofi, Bayer AG, Amgen Inc., and Merck are some of the key players in the appendiceal cancer treatment market.


Regional Market Summary


Global Appendiceal Cancer Treatment Market Share (%), by Region, 2017


Appendiceal Cancer Treatment Market Share


Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The appendiceal cancer treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European appendiceal cancer treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The appendiceal cancer treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East and Africa has been segmented into the Middle East and Africa.


Geographically, the Americas is anticipated to dominate the global appendiceal cancer treatment owing to favorable reimbursement scenario and focus of the government on growing number of rare cancers. According to the American Cancer Society, it affects less than 1000 people each year and accounts for about five percent of all gastrointestinal cancers in the US.


Europe is expected to hold the second largest position in the appendiceal cancer treatment market. The market growth in this region is attributed to the growing prevalence of cancers and increasing healthcare expenditure.


Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cancer cases in China in 2015.


On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to a well-developed healthcare sector and growth initiatives by private healthcare companies.


Appendiceal cancer treatment market, by Type



  • Neuroendocrine tumors

  • Carcinomas

  • Mucinous adenocarcinoma

  • Goblet cell carcinoids

  • Intestinal-type adenocarcinoma

  • Signet-ring cell adenocarcinoma

  • Paraganglioma


Appendiceal cancer treatment market, by Treatment



  • Surgery


    • Appendectomy

    • Hemicolectomy

    • Cytoreduction


  • Chemotherapy

  • Hyperthermic Intraperitoneal Chemotherapy

  • Systemic Chemotherapy

  • Radiation Therapy


Appendiceal cancer treatment market, by End-User



  • Hospitals and clinics

  • Cancer research institutes

  • Others


Appendiceal cancer treatment market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific



  • Middle East & Africa



  • Middle East

  • Africa



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


The Appendiceal Cancer Treatment Market would be restrained by strict government regulations regarding product approvals.

Factors like innovation in products and better awareness would drive Appendiceal Cancer Treatment Market ahead.

Types included in the Appendiceal Cancer Treatment Market are neuroendocrine tumors and carcinomas.

The treatments are surgery, chemotherapy, and radiation therapy included in the discussion of Appendiceal Cancer Treatment Market report.

Appendectomy, cytoreduction, and hemicolectomy are surgery types included in Appendiceal Cancer Treatment Market report

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Appendiceal Cancer Treatment Market, by Type

6.1 Introduction

6.2 Neuroendocrine tumors

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Carcinomas

6.3.1 Mucinous adenocarcinoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.2 Goblet cell carcinoids

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.3 Intestinal-type adenocarcinoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.4 Signet-ring cell adenocarcinoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.5 Paraganglioma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Appendiceal Cancer Treatment Market, by Treatment

7.1 Introduction

7.2 Surgery

7.2.1 Appendectomy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.2 Hemicolectomy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.3 Cytoreduction

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Chemotherapy

7.3.1 Hyperthermic Intraperitoneal Chemotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.2 Systemic Chemotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 Radiation Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Appendiceal Cancer Treatment Market, by End-User

8.1 Hospitals

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2 Cancer Research Institutes

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Appendiceal Cancer Treatment Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 AbbVie, Inc.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Pfizer Inc.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Eli Lilly and Company

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Bristol-Myers Squibb Company

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 F. Hoffman-La Roche Ltd.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Becton, Dickinson & Company

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Novartis AG

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 General Electric Company

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 AstraZeneca

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Boehringer Ingelheim International GmbH

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Teva Pharmaceutical Industries Ltd.

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Sanofi

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Bayer AG

11.13.1 Overview

11.13.2 Product Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 Amgen Inc.

11.14.1 Overview

11.14.2 Product Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.15 Merck

11.15.1 Overview

11.15.2 Product Overview

11.15.3 Financials

11.15.4 Key Developments

11.15.5 SWOT Analysis

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Appendiceal Cancer Treatment Industry

Chapter 13. Appendix


LIST OF TABLES

Table 1 Global Appendiceal Cancer Treatment Market Synopsis, 2020–2027

Table 2 Global Appendiceal Cancer Treatment Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Appendiceal Cancer Treatment Market, by Type, 2020–2027 (USD Million)

Table 4 Global Appendiceal Cancer Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 5 Global Appendiceal Cancer Treatment Market, by End-User, 2020–2027 (USD Million)

Table 6 Global Appendiceal Cancer Treatment Market, by Region, 2020–2027(USD Million)

Table 7 North America: Appendiceal Cancer Treatment Market, by Type, 2020–2027 (USD Million)

Table 8 North America: Appendiceal Cancer Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 9 North America: Appendiceal Cancer Treatment Market, by End-User, 2020–2027 (USD Million)

Table 10 North America: Appendiceal Cancer Treatment Market, by Region, 2020–2027 (USD Million)

Table 11 US: Appendiceal Cancer Treatment Market, by Type, 2020–2027 (USD Million)

Table 12 US: Appendiceal Cancer Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 13 US: Appendiceal Cancer Treatment Market, by End-User, 2020–2027 (USD Million)

Table 14 US: Appendiceal Cancer Treatment Market, by Region, 2020–2027 (USD Million)

Table 15 Canada: Appendiceal Cancer Treatment Market, by Type, 2020–2027 (USD Million)

Table 16 Canada: Appendiceal Cancer Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 17 Canada: Appendiceal Cancer Treatment Market, by End-User, 2020–2027 (USD Million)

Table 18 Canada: Appendiceal Cancer Treatment Market, by Region, 2020–2027 (USD Million)

Table 19 South America: Appendiceal Cancer Treatment Market, by Type, 2020–2027 (USD Million)

Table 20 South America: Appendiceal Cancer Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 21 South America: Appendiceal Cancer Treatment Market, by End-User, 2020–2027 (USD Million)

Table 22 South America: Appendiceal Cancer Treatment Market, by Region, 2020–2027 (USD Million)

Table 23 Europe: Appendiceal Cancer Treatment Market, by Type, 2020–2027 (USD Million)

Table 24 Europe: Appendiceal Cancer Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 25 Europe: Appendiceal Cancer Treatment Market, by End-User, 2020–2027 (USD Million)

Table 26 Europe: Appendiceal Cancer Treatment Market, by Region, 2020–2027 (USD Million)

Table 27 Western Europe: Appendiceal Cancer Treatment Market, by Type, 2020–2027 (USD Million)

Table 28 Western Europe: Appendiceal Cancer Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 29 Western Europe: Appendiceal Cancer Treatment Market, by End-User, 2020–2027 (USD Million)

Table 30 Western Europe: Appendiceal Cancer Treatment Market, by Region, 2020–2027 (USD Million)

Table 31 Eastern Europe: Appendiceal Cancer Treatment Market, by Type, 2020–2027 (USD Million)

Table 32 Eastern Europe: Appendiceal Cancer Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 33 Eastern Europe: Appendiceal Cancer Treatment Market, by End-User, 2020–2027 (USD Million)

Table 34 Eastern Europe: Appendiceal Cancer Treatment Market, by Region, 2020–2027 (USD Million)

Table 35 Asia-Pacific: Appendiceal Cancer Treatment Market, by Type, 2020–2027 (USD Million)

Table 35 Asia-Pacific: Appendiceal Cancer Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 36 Asia-Pacific: Appendiceal Cancer Treatment Market, by End-User, 2020–2027 (USD Million)

Table 37 Asia-Pacific: Appendiceal Cancer Treatment Market, by Region, 2020–2027 (USD Million)

Table 38 Middle East & Africa: Appendiceal Cancer Treatment Market, by Type, 2020–2027 (USD Million)

Table 39 Middle East & Africa: Appendiceal Cancer Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 40 Middle East & Africa: Appendiceal Cancer Treatment Market, by End-User, 2020–2027 (USD Million)

Table 41 Middle East & Africa: Appendiceal Cancer Treatment Market, by Region, 2020–2027 (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Appendiceal Cancer Treatment Market

Figure 3 Segmentation Market Dynamics for Global Appendiceal Cancer Treatment Market

Figure 4 Global Appendiceal Cancer Treatment Market Share, by Type, 2020 (%)

Figure 5 Global Appendiceal Cancer Treatment Market Share, by Treatment, 2020 (%)

Figure 6 Global Appendiceal Cancer Treatment Market Share, by End-User, 2020 (%)

Figure 7 Global Appendiceal Cancer Treatment Market Share, by Region, 2020 (%)

Figure 8 North America: Appendiceal Cancer Treatment Market Share, by Country, 2020 (%)

Figure 9 Europe: Appendiceal Cancer Treatment Market Share, by Country, 2020 (%)

Figure 10 Asia-Pacific: Appendiceal Cancer Treatment Market Share, by Country, 2020 (%)

Figure 11 Middle East & Africa: Appendiceal Cancer Treatment Market Share, by Country, 2020 (%)

Figure 12 Global Appendiceal Cancer Treatment Market: Company Share Analysis, 2020 (%)

Figure 13 AbbVie, Inc.: Key Financials

Figure 14 AbbVie, Inc.: Segmental Revenue

Figure 15 AbbVie, Inc.: Geographical Revenue

Figure 16 Pfizer Inc.: Key Financials

Figure 17 Pfizer Inc.: Segmental Revenue

Figure 18 Pfizer Inc.: Geographical Revenue

Figure 19 Eli Lilly and Company: Key Financials

Figure 20 Eli Lilly and Company: Segmental Revenue

Figure 21 Eli Lilly and Company: Geographical Revenue

Figure 22 Bristol-Myers Squibb Company: Key Financials

Figure 23 Bristol-Myers Squibb Company: Segmental Revenue

Figure 24 Bristol-Myers Squibb Company: Geographical Revenue

Figure 25 F. Hoffman-La Roche Ltd.: Key Financials

Figure 26 F. Hoffman-La Roche Ltd.: Segmental Revenue

Figure 27 F. Hoffman-La Roche Ltd.: Geographical Revenue

Figure 28 Becton, Dickinson & Company: Key Financials

Figure 29 Becton, Dickinson & Company: Segmental Revenue

Figure 30 Becton, Dickinson & Company: Geographical Revenue

Figure 31 Novartis AG: Key Financials

Figure 32 Novartis AG: Segmental Revenue

Figure 33 Novartis AG: Geographical Revenue

Figure 34 General Electric Company: Key Financials

Figure 35 General Electric Company: Segmental Revenue

Figure 36 General Electric Company: Geographical Revenue

Figure 37 AstraZeneca: Key Financials

Figure 38 AstraZeneca: Segmental Revenue

Figure 39 AstraZeneca: Geographical Revenue

Figure 40 Boehringer Ingelheim International GmbH: Key Financials

Figure 41 Boehringer Ingelheim International GmbH: Segmental Revenue

Figure 42 Boehringer Ingelheim International GmbH: Geographical Revenue

Figure 43 Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 44 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 45 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 46 Sanofi: Key Financials

Figure 47 Sanofi: Segmental Revenue

Figure 48 Sanofi: Geographical Revenue

Figure 49 Bayer AG: Key Financials

Figure 50 Bayer AG: Segmental Revenue

Figure 51 Bayer AG: Geographical Revenue

Figure 52 Amgen Inc.: Key Financials

Figure 53 Amgen Inc.: Segmental Revenue

Figure 54 Amgen Inc.: Geographical Revenue

Figure 55 Merck: Key Financials

Figure 56 Merck: Segmental Revenue

Figure 57 Merck: Geographical Revenue